Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
The efficacy and safety profile of naltrexone-bupropion has been established by several multicentre randomised double-blind placebo-controlled trials in the Contrave Obesity Research (COR) programme, including the Contrave Obesity Research-I (COR-I) study, the Contrave Obesity Research-II (COR-II) study, and the Contrave Obesity Research-Intensive Behavior Modification study (COR-BMOD) [9,10,11]
In 8 options it covers three FDA black-box warning conditions (MTC family history, MEN2 family history, pancreatitis), two absolute GLP-1 contraindications (Type 1 diabetes, pregnancy), and two safety-critical behavioral flags (active eating disorder, substance abuse)
It's specifically intended for those who have been clinically diagnosed as obese and find it challenging to lose weight through diet and exercise alone
Lancet Diabetes Endocrinol 7(11):845854
US$ 26.26
US$ 22.33
US$ 22.97
US$ 29.20
US$ 28.86
US$ 29.45
